Germany Journal

Document Type : Original Article


1 PhD student of Medical Education, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of medical sciences.

2 Imam Khomeini Medical and Research Centre, Tehran University of Medical Sciences, Tehran, Iran.


Background and purpose:  Despite many developments in the health care of cardiac surgery patients, yet 5%–30% of them may become challenged due to renal dysfunction, delirium, and arrhythmia. Eliminating or reducing these unwanted outcomes is likely to improve the prognosis of them. Several studies suggested that dexmedetomidine (DEX), a highly selective short-acting α-2 adrenergic agonist predominantly used for anti-delirium and sedative characteristics, may be useful for reducing the adverse effect of cardiac surgeries. The purpose of the current study was to investigate the outcome of the administration of DEX in patients undergoing cardiac surgeries. 
Materials and Methods: We included the data from patents who underwent coronary artery bypass grafting (CABG) without a valve, CABG with valve surgery, and valve-only surgery from August 2018 to November 2018. A total of 51 patients were eligible for our study after extraction. For the DEX group, the infusion of DEX was started 10 min before anesthesia induction in a 0.2–0.6 µg/Kg/h rate. And the same amount of normal saline (0.9%) was infused for the control group. The infusion was continued post-operatively until extubation (maximum for 24 h). The patients were compared primarily for Acute Kidney Injury (AKI), delirium, new-onset atrial fibrillation (AF) rhythm.
Results:  We had a total of 51 patients among which 33 (64.70%) received DEX, and 18 (35.29%) received a placebo. There was no significant difference between groups for demographic data. One patient (16.7%) from the DEX group and five patients (83.3%) from the control group revealed an AF rhythm after surgery (p=0.009). No patient faced delirium. Seven patients seemed to be AKI, of which five (71.4%) were in the DEX group and two (28.6%) were in the control group (p>0.05).
Conclusion: There might be a meaningful reduction of new-onset AF rhythm in adult patients who use DEX after cardiac surgeries.